4/10
04:30 pm
rigl
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
4/4
08:10 am
rigl
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma [Yahoo! Finance]
Medium
Report
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma [Yahoo! Finance]
4/4
08:05 am
rigl
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Low
Report
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
4/4
02:08 am
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
3/27
11:02 pm
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Neutral
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/19
02:09 am
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
3/14
10:59 am
rigl
Lexaria appoints Nelson Cabatuan as CFO [Seeking Alpha]
Medium
Report
Lexaria appoints Nelson Cabatuan as CFO [Seeking Alpha]
3/12
07:58 pm
rigl
Global Immune Thrombocytopenia Drug Markets, 2019-2022 and 2023-2029: Advanced Drug Delivery Technologies Transform Management, Second-Generation TPO-RAs Revolutionize Treatment Options [Yahoo! Finance]
Low
Report
Global Immune Thrombocytopenia Drug Markets, 2019-2022 and 2023-2029: Advanced Drug Delivery Technologies Transform Management, Second-Generation TPO-RAs Revolutionize Treatment Options [Yahoo! Finance]
3/12
08:31 am
rigl
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer [Yahoo! Finance]
Low
Report
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer [Yahoo! Finance]
3/12
08:05 am
rigl
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Low
Report
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
3/11
11:00 pm
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/11
11:00 pm
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/7
02:06 pm
rigl
Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year [Yahoo! Finance]
Neutral
Report
Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year [Yahoo! Finance]
3/7
12:17 pm
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/7
10:24 am
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Citigroup Inc. from $3.00 to $4.00. They now have a "buy" rating on the stock.
Medium
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Citigroup Inc. from $3.00 to $4.00. They now have a "buy" rating on the stock.
3/6
12:35 pm
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Cantor Fitzgerald from $2.00 to $3.00. They now have a "neutral" rating on the stock.
Medium
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its price target raised by analysts at Cantor Fitzgerald from $2.00 to $3.00. They now have a "neutral" rating on the stock.
3/6
11:01 am
rigl
Owning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), [Yahoo! Finance]
Medium
Report
Owning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), [Yahoo! Finance]
3/6
09:37 am
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
3/6
08:40 am
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $1.25 price target on the stock.
Medium
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $1.25 price target on the stock.
3/5
04:10 pm
rigl
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/5
04:01 pm
rigl
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/27
08:05 am
rigl
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
Medium
Report
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
2/23
09:13 am
rigl
Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report [Seeking Alpha]
Medium
Report
Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report [Seeking Alpha]
2/22
12:31 pm
rigl
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
2/22
07:56 am
rigl
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® [Yahoo! Finance]
Medium
Report
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO® [Yahoo! Finance]